Skip to main content
Pipeline

Pipeline Programs

  Discovery

    Preclinical

 Phase 1

 Phase 2

Phase 3

EB-003

Difficult-to-Treat Mental Health Disorders
Prescription Model

Next Milestone: Pre-IND FDA Meeting

40%

EB-002

Psychiatric Disorders
Administered in Clinical Setting

Next Milestone: Inititate FIH in Australia

40%

EB-003

Prescription Model

Highlights

  • Moderate dose
  • Prescription model
  • Taken regularly
  • Minimal side effects and reduced hallucinations
  • Available to a large patient population

Enveric is advancing its EB-003, expected to offer a first-in-class, new approach to the treatment of difficult-to-address anxiety, depression and other disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.

Synopsis of Target Benefits

  • Reduced hallucination profile
  • Improved cardiac safety
  • Orally bioavailable, chronic administration
  • Treatment in clinic not required
  • Drug intended to be prescribed for regular maintenance and taken at times and in settings more convenient to patient

EB-002

Administered in Clinical Setting

Highlights

  • High dose
  • Clinical setting
  • One course of therapy potentially provides benefit for months
  • Treatment is associated with hallucinations
  • Appropriate for a limited patient population

Enveric’s Psybrary™ has given rise to the EVM201 Series, next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite—psilocin. Enveric’s has completed screening and characterization of its portfolio of psilocin prodrugs, comprised of nine distinct classes. All molecules were rationally designed to achieve altered metabolic and pharmacokinetic properties with the intention of improving the drug-like properties and pharmacological profile of EVM201 drug candidates compared to the natural compound, psilocybin.

Enveric is developing the first product from the EVM201 Series – EB-002 – for the treatment of psychiatric disorders.

Synopsis of Target Benefits

  • Altered metabolic and pharmacokinetic properties relative to psilocybin to achieve improved risk/benefit profile
  • Flexible delivery route – potential for oral, intra-nasal, buccal or intravenous route for
    • Faster access to target receptor and target location
    • Therapeutic benefit at lower dose
    • Reduced GI Upset
  • Faster-acting, shorter duration